|
Novartis’ Afinitor Gets EU Approval to Treat Pancreatic Tumors
The European Commission is expanding the indication for Novartis’ Afinitor to include treatment of advanced pancreatic neuroendocrine tumors (PNET) following the FDA’s May approval for the indication.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives